Detalhe da pesquisa
1.
A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease.
J Pharmacol Exp Ther
; 381(1): 33-41, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35110393
2.
Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
Mult Scler
; 26(8): 955-963, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31144568
3.
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Mult Scler
; 26(1): 48-56, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30785358
4.
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Mult Scler
; 26(13): 1719-1728, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31675266
5.
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
Mult Scler
; 25(9): 1273-1288, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30986126
6.
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
Mult Scler
; 25(12): 1605-1617, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30289355
7.
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Mult Scler
; 23(10): 1367-1376, 2017 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-27885061
8.
Ataxia, dementia, and hypogonadotropism caused by disordered ubiquitination.
N Engl J Med
; 368(21): 1992-2003, 2013 May 23.
Artigo
Inglês
| MEDLINE | ID: mdl-23656588
9.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Lancet
; 380(9856): 1829-39, 2012 Nov 24.
Artigo
Inglês
| MEDLINE | ID: mdl-23122650
10.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Lancet
; 380(9856): 1819-28, 2012 Nov 24.
Artigo
Inglês
| MEDLINE | ID: mdl-23122652
11.
A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Blood
; 118(24): 6299-305, 2011 Dec 08.
Artigo
Inglês
| MEDLINE | ID: mdl-21960587
12.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Mult Scler
; 19(10): 1302-9, 2013 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-23459567
13.
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
Mult Scler J Exp Transl Clin
; 9(1): 20552173221142741, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36619856
14.
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
Neuropsychopharmacology
; 47(3): 711-718, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34667294
15.
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
N Engl J Med
; 359(17): 1786-801, 2008 Oct 23.
Artigo
Inglês
| MEDLINE | ID: mdl-18946064
16.
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
Ther Adv Neurol Disord
; 14: 1756286420982134, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34035833
17.
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.
Mult Scler J Exp Transl Clin
; 6(4): 2055217320972137, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-33414927
18.
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
Neurology
; 89(11): 1107-1116, 2017 Sep 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28835401
19.
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
Neurology
; 89(11): 1117-1126, 2017 Sep 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28835403
20.
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
J Neurol Sci
; 363: 188-94, 2016 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-27000249